在2型炎症的COPD患者中,降低了用生物药物治疗的全身葡萄糖皮质体的利用率
Truong-An A Ho1, Stephen Dachert2, Anugya Mittal3
1Department of Thoracic Medicine and Surgery, Lewis Katz School of Medicine, PA, Philadelphia, 19140, USA. truong-an.ho@tuhs.temple.edu.
BMC pulmonary medicine
|July 10, 2025
概括
生物疗法显著减少了慢性阻塞性肺病 (COPD) 患者的全身葡萄糖皮质激素的使用,这些患者患有2型炎症. 这一发现表明,生物药物可以降低COPD管理中的葡萄糖皮质类药物副作用负担.
科学领域:
- 肺部病理学 肺部病理学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 系统性皮质糖类药物对于治疗慢性阻塞性肺病 (COPD) 的急性恶化至关重要.
- 针对COPD2型 (T2) 炎症的生物疗法在减少恶化方面显示出有前途.
- 生物制剂对COPD患者全身葡萄糖皮质类药物利用的影响尚不清楚.
研究的目的:
- 调查生物疗法是否可以减少COPD和T2炎症患者系统性葡萄糖皮质激素使用的整体负担.
- 在生物启动前和之后量化葡萄糖皮质体分配频率和累积剂量的变化.
主要方法:
- 从2016年到2023年对电子医疗记录的回顾性审查.
- 包括用生物药物治疗的COPD患者.
- 收集有关人口统计数据,并发病,乙素细胞计数,肺功能和葡萄糖皮质激素分配报告的数据.
- 主要结局:每年使用葡萄糖皮质激素的变化和生物治疗前后的累积剂量.
主要成果:
- 分析了56名COPD患者 (平均年龄为71岁).
- 生物药物显著减少了每年使用葡萄糖皮质体的数量 (平均减少1.16,p=0.002).
- 生物显著降低了累积的系统性葡萄糖皮质体剂量 (平均减少413.2毫克,p=0.001).
- 没有发现基线氨酸细胞计数和葡萄糖皮质激素利用之间有强烈的关联.
结论:
- 生物疗法与T2炎症COPD患者全身葡萄糖皮质类药物使用的显著减少有关.
- 这种减量适用于分配频率和总剂量.
- 生物药物有可能在COPD管理中减轻与葡萄糖皮质类药物相关的不良影响.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
208
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
208
COPD: Management Using Bronchodilators and Corticosteroids
322
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
322
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
398
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
398
Drugs Used in Lower Respiratory Disorders: Overview
610
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
610
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
275
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
275
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
238
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
238


